Enveric Biosciences announces successful preclinical pharmacokinetic (PK) studies for its lead drug candidate, EB-003, a non-hallucinogenic DMT analog designed to treat depression and anxiety. The results show significant brain penetration and pave the way for an Investigational New Drug (IND) application in 2025, targeting a multi-billion dollar market.
The global market for plant-based Active Pharmaceutical Ingredients (APIs) is booming, projected to reach $52.1 billion by 2034, driven by increasing demand for natural and sustainable solutions, particularly psychedelics and cannabis-derived compounds. This surge is fueled by therapeutic applications and significant investments in Asian markets.
Elite golfers are turning to psychedelics like psilocybin and ayahuasca to gain a mental edge on the course. While the practice remains niche, a growing number of professional players are embracing microdosing to improve focus, reduce anxiety, and enhance performance. This trend signals a shift in the culture of sports wellness, challenging the traditional reliance on pharmaceuticals.
A new study reveals that a majority of Americans support the use of psilocybin, the active compound in magic mushrooms, in controlled, licensed settings for both mental health treatment and personal well-being. This bipartisan support highlights a growing openness towards psychedelic therapy, despite ongoing concerns about responsible implementation.
Republican Senator JD Vance, known for his conservative stance, expressed openness to exploring psychedelic therapy for veterans during a recent Joe Rogan podcast appearance. This shift in perspective follows Vance’s acknowledgment of the potential benefits of substances like MDMA and psilocybin, alongside Rogan’s insights on the history and benefits of psychedelic therapies. While advocating for a ‘live and let live’ approach to cannabis, Vance’s curiosity about psychedelic therapies for veterans and his questioning of federal drug policy hurdles mark a potential evolution in his stance on drug policy.
Former ‘Buffy the Vampire Slayer’ star Eliza Dushku is using her personal experience with psychedelic-assisted therapy to advocate for the legalization and regulation of psychedelics in Massachusetts. Joining forces with healthcare professionals and her husband, she’s pushing for Ballot Question 4, which aims to create a state commission to oversee the use of psychedelics for therapeutic purposes.
Researchers at Johns Hopkins University have discovered that the psychedelic drug DOI (2,5-dimethoxy-4-iodoamphetamine) reduces anxiety by activating specific neurons in the brain. The study, published in Neuron, reveals that DOI works by influencing parvalbumin-positive interneurons in the ventral hippocampus, leading to a decrease in anxiety-related activity. The findings suggest potential therapeutic benefits for anxiety disorders without the hallucinogenic effects commonly associated with psychedelics.
Trinity College Dublin is at the forefront of a growing movement exploring the therapeutic potential of psychedelics. The inaugural Irish conference on psychedelics, hosted by Trinity and in collaboration with Irish Doctors for Psychedelic Assisted Therapy, highlights emerging research on these substances as potential treatments for mental health conditions like depression and addiction. The conference also marks the launch of Trinity’s new Psychedelic Research Group (PRG), which aims to advance understanding of psychedelics’ therapeutic applications amid growing global interest.
A new study published in the Journal of Psychopharmacology explores the fascinating connection between DMT, a powerful psychedelic, and the body’s autonomic nervous system. Researchers found that profound, mystical experiences often reported by DMT users are linked to specific heart activity patterns, suggesting that the body’s response to stress and relaxation plays a crucial role in shaping psychedelic effects.
A crucial victory for psychedelic research advocates! A DEA administrative law judge has rejected the agency’s attempt to exclude crucial witnesses and evidence in an upcoming hearing challenging the DEA’s proposed ban on two psychedelic compounds, DOI and DOC. The judge’s decision is a major win for those who argue that the DEA’s proposed ban is unjustified and could severely hinder scientific exploration of the potential therapeutic benefits of these compounds.
